ClinicaliQ Trial Snapshot
- SAPIEN 3 Ultra System PMCF — Active Not Recruiting • NCT04555967.
- Edwards SAPIEN 3 Ultra valve reduces symptoms in patients with severe aortic stenosis, confirming safety and effectiveness in real-world use.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A post-market study of the Edwards SAPIEN 3 Ultra System in subjects with symptomatic, severe, calcific aortic stenosis. Conditions: Aortic Valve Stenosis Interventions: SAPIEN 3 Ultra System Lead Sponsor: Edwards Lifesciences Planned Enrollment: 200 participants